38609-97-1

38609-97-1 structure

Name: 2-(9-Oxoacridin-10(9H)-yl)acetic acid
Chemical Name: 9-Oxo-10(9H)-acridineacetic acid
CAS Number: 38609-97-1
Molecular Formula: C₁₅H₁₁NO₃
Molecular Weight: 253.253
Catalog: analytical chemistry Analytical reagent Common analytical reagents
Create Date: 2018-08-25 11:52:20
Modify Date: 2025-08-31 08:26:20
Cridanimod is a small-molecule immunomodulator and interferon inducer[1]. Cridanimod is a potent progesterone receptor (PR) activator mediated through induction of IFNα and IFNβ expression[2].

Name	9-Oxo-10(9H)-acridineacetic acid
Synonyms	cridanimod (9,10-Dihydro-9-oxo-10-acridinyl)acetic acid MFCD00157050 (9-Oxo-10(9H)-acridinyl)acetic acid 9-Oxo-10(9H)-acridineacetic acid (9-oxoacridin-10(9H)-yl)acetic acid 10-(Carboxymethyl)-9(10H)-acridone 2-(9-oxoacridin-10-yl)acetic acid 10(9H)-Acridineacetic acid, 9-oxo- 9-Oxoacridine-10-acetic Acid 10-(Carboxymethyl)-9(10H)acridone (9,10-Dihydro-9-oxo-10-acridinyl)acetic acid (10-(Carboxymethyl)-9(10H)acridone

Description	Cridanimod is a small-molecule immunomodulator and interferon inducer[1]. Cridanimod is a potent progesterone receptor (PR) activator mediated through induction of IFNα and IFNβ expression[2].
Related Catalog	Signaling Pathways >> Others >> Progesterone Receptor Signaling Pathways >> Immunology/Inflammation >> IFNAR Research Areas >> Inflammation/Immunology
Target	PR, IFNα, IFNβ[1]
In Vivo	Cridanimod (IM; 1-6 mg; twice a week) has a significantly longer survival time. Cridanimod significant increases in IFNα and -β in cridanimod-treated mice in a dose-dependent manner[1]. Animal Model: Athymic mice with hec50co cells[1] Dosage: 1, 3, 6 mg Administration: IM; twice a week Result: Had a significantly longer survival time.
References	[1]. Xenetic Biosciences Announces FDA Acceptance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of Virexxa® in Endometrial Cancer. AUGUST 19, 2016 [2]. Matthew J. Carlson, et al. Cridanimod and progestin therapy in hormone-resistant endometrial cancer. Journal of Clinical Oncology, January 30, 2017.

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 6,408,1981

Symbol	GHS07
Signal Word	Warning
Hazard Statements	H315-H319-H335
Precautionary Statements	P261-P305 + P351 + P338
Personal Protective Equipment	dust mask type N95 (US);Eyeshields;Gloves
Hazard Codes	Xi: Irritant;
Risk Phrases	R36/37/38
Safety Phrases	26
RIDADR	NONH for all modes of transport
WGK Germany	3
RTECS	AR7190000
HS Code	2933990090

HS Code	2933990090
Summary	2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%